- cafead Nov 18, 2021 at 10:32: AM
via As the future of machine learning and AI promises to make major breakthroughs in drug development, a suite of startups is looking to scale their own competing robot brain trusts. An ambitious startup out of Flagship Pioneering’s incubator uncloaked last year with its own spin in that arms race — and now it’s primed and ready for a major expansion in the coming years.
Generate Biomedicines has closed a giant $370 million Series B from founding investor Flagship as well as Alaska Permanent Fund, Altitude Life Science Ventures, ARCH Venture Partners, and funds and accounts advised by T. Rowe Price Associates, the company said.
article source
Generate Biomedicines has closed a giant $370 million Series B from founding investor Flagship as well as Alaska Permanent Fund, Altitude Life Science Ventures, ARCH Venture Partners, and funds and accounts advised by T. Rowe Price Associates, the company said.
article source